Brief: IGM Biosciences Announces First Quarter 2023 Financial Results
12/05/2023 14:10
May 12 (Reuters) - IGM Biosciences Inc IGMS.O :
* IGM BIOSCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* IGM BIOSCIENCES INC - PLANS TO BEGIN CLINICAL TESTING OF
IMVOTAMAB IN SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS AND SEVERE
RHEUMATOID ARTHRITIS
* IGM BIOSCIENCES INC - CASH AND INVESTMENTS AS OF MARCH 31,
2023
WERE $373.4 MILLION
* IGM BIOSCIENCES INC-QTRLY LOSS PER SHARE $1.33
* IGM BIOSCIENCES INC - EXPECTS TO END 2023 WITH A BALANCE
OF MORE
THAN $200 MILLION IN CASH AND INVESTMENTS
* IGM BIOSCIENCES INC - EXPECTS CASH BALANCE TO FUND ITS
OPERATING
EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2024
Source text for Eikon: ID:nGNX7HZp1p
Further company coverage: IGMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGM Biosciences
See all newsU.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
IGM Biosciences rises on buyout deal with Concentra Biosciences
Brief: Igm Biosciences Enters Into Agreement To Be Acquired By Concentra Biosciences For $1.247 In Cash Per Share Plus A Contingent Value Right
IGM Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary